Reduced Graphene Oxides Modulate the Expression of Cell Receptors and Voltage-Dependent Ion Channel Genes of Glioblastoma Multiforme

The development of nanotechnology based on graphene and its derivatives has aroused great scientific interest because of their unusual properties. Graphene (GN) and its derivatives, such as reduced graphene oxide (rGO), exhibit antitumor effects on glioblastoma multiforme (GBM) cells in vitro. The antitumor activity of rGO with different contents of oxygen-containing functional groups and GN was compared. Using FTIR (fourier transform infrared) analysis, the content of individual functional groups (GN/exfoliation (ExF), rGO/thermal (Term), rGO/ammonium thiosulphate (ATS), and rGO/ thiourea dioxide (TUD)) was determined. Cell membrane damage, as well as changes in the cell membrane potential, was analyzed. Additionally, the gene expression of voltage-dependent ion channels (clcn3, clcn6, cacna1b, cacna1d, nalcn, kcne4, kcnj10, and kcnb1) and extracellular receptors was determined. A reduction in the potential of the U87 glioma cell membrane was observed after treatment with rGO/ATS and rGO/TUD flakes. Moreover, it was also demonstrated that major changes in the expression of voltage-dependent ion channel genes were observed in clcn3, nalcn, and kcne4 after treatment with rGO/ATS and rGO/TUD flakes. Furthermore, the GN/ExF, rGO/ATS, and rGO/TUD flakes significantly reduced the expression of extracellular receptors (uPar, CD105) in U87 glioblastoma cells. In conclusion, the cytotoxic mechanism of rGO flakes may depend on the presence and types of oxygen-containing functional groups, which are more abundant in rGO compared to GN.     

One-step chemical reduction of graphene oxide with oligothiophene for improved electrocatalytic oxygen reduction reactions

Oligothiophene (nTP, n = 1, 2, 3) has been used as the reductant for the first time in the preparation of graphene by the reduction of graphene oxide (GO). A simple single-step chemical approach has been developed to reduce and/or functionalize GO with nTP. The reaction takes place at room temperature under stirring of a suspension of GO and nTP in MeCN. The nTP has been grafted onto the surface of GO by reacting epoxy groups together with the reduced graphene oxide (rGO). It was observed that increasing the thiophene ring (hereafter, thiophene is referred to as TP; 2,2′ bithiophene as 2TP; and 2,2′:5′,2″ terthiophene as 3TP) can enhance the reduction reaction. All instrumental experiments have confirmed that nTP not only covalently bonded to the GO but also partly restored the conjugate structure of GO, as a reducing agent. The resultant rGO with 3TP (rGO3TP) has been demonstrated to show remarkable electrocatalytic activity toward oxygen reduction reaction (ORR) compared to typical rGO. The observed ORR electrocatalytic activity induced by the intermolecular charge-transfer provides a general approach to various carbon-based metal-free ORR catalysts.     

Bisdemethoxycurcumin Induces Cell Apoptosis and Inhibits Human Brain Glioblastoma GBM 8401/Luc2 Cell Xenograft Tumor in Subcutaneous Nude Mice In Vivo

Bisdemethoxycurcumin (BDMC) has biological activities, including anticancer effects in vitro; however, its anticancer effects in human glioblastoma (GBM) cells have not been examined yet. This study aimed to evaluate the tumor inhibitory effect and molecular mechanism of BDMC on human GBM 8401/luc2 cells in vitro and in vivo. In vitro studies have shown that BDMC significantly reduced cell viability and induced cell apoptosis in GBM 8401/luc2 cells. Furthermore, BDMC induced apoptosis via inhibited Bcl-2 (anti-apoptotic protein) and increased Bax (pro-apoptotic proteins) and cytochrome c release in GBM 8401/luc2 cells in vitro. Then, twelve BALB/c-nude mice were xenografted with human glioblastoma GBM 8401/luc2 cancer cells subcutaneously, and the xenograft nude mice were treated without and with BDMC (30 and 60 mg/kg of BDMC treatment) every 3 days. GBM 8401/luc2 cell xenografts experiment showed that the growth of the tumors was significantly suppressed by BDMC administration at both doses based on the reduction of tumor size and weights. BDMC did not change the body weight and the H&E histopathology analysis of liver samples, indicating that BDMC did not induce systemic toxicity. Meanwhile, treatment with BDMC up-regulated the expressions of BAX and cleaved caspase-3, while it down-regulated the protein expressions of Bcl-2 and XIAP in the tumor tissues compared with the control group. This study has demonstrated that BDMC presents potent anticancer activity on the human glioblastoma GBM 8401/luc2 cell xenograft model by inducing apoptosis and inhibiting tumor cell proliferation and shows the potential for further development to the anti-GBM cancer drug.     

Benefits in the Macrophage Response Due to Graphene Oxide Reduction by Thermal Treatment

Graphene and its derivatives are very promising nanomaterials for biomedical applications and are proving to be very useful for the preparation of scaffolds for tissue repair. The response of immune cells to these graphene-based materials (GBM) appears to be critical in promoting regeneration, thus, the study of this response is essential before they are used to prepare any type of scaffold. Another relevant factor is the variability of the GBM surface chemistry, namely the type and quantity of oxygen functional groups, which may have an important effect on cell behavior. The response of RAW-264.7 macrophages to graphene oxide (GO) and two types of reduced GO, rGO15 and rGO30, obtained after vacuum-assisted thermal treatment of 15 and 30 min, respectively, was evaluated by analyzing the uptake of these nanostructures, the intracellular content of reactive oxygen species, and specific markers of the proinflammatory M1 phenotype, such as CD80 expression and secretion of inflammatory cytokines TNF-α and IL-6. Our results demonstrate that GO reduction resulted in a decrease of both oxidative stress and proinflammatory cytokine secretion, significantly improving its biocompatibility and potential for the preparation of 3D scaffolds able of triggering the appropriate immune response for tissue regeneration.     

Resveratrol Modulation of Apoptosis and Cell Cycle Response to Cisplatin in Head and Neck Cancer Cell Lines

In head and neck cancers, the effectiveness of cisplatin (CisPt) treatment is limited by its toxicity, especially when higher doses are necessary, and the possible occurrence of cisplatin resistance. This study evaluated the effects of resveratrol (RSV) on the expression of different genes involved in the response of human tumor cells (FaDu, PE/CA-PJ49) to cisplatin therapy. Our results revealed that RSV induced apoptosis amplification in both FaDu and PE/CA-PJ49 cells and modulated the expression of specific genes differently than in normal HaCaT cells. In FaDu cells, combined CisPt + RSV treatment induced an increase in apoptosis, which was associated with an increase in c-MYC and TP53 and a decrease in BCL-2 expression. While CisPt + RSV treatment induced apoptosis in PE/CA-PJ49 cells by inhibition of BCL-2 associated with high levels of MDM-2 and subsequently led to inhibition of TP53 gene expression. Decreased c-MYC expression in PE/CA-PJ49 treated with CisPt + RSV was accompanied by cell cycle blockage in G0/G1 phase. In conclusion, RSV influences tumor cell response to CisPt by inducing apoptosis and modulating gene expression. In addition, in normal HaCaT cells, RSV was able to reduce the harmful effects of CisPt.     

Strontium incorporated hydroxyapatite/hydrothermally reduced graphene oxide nanocomposite as a cytocompatible material

Hydroxyapatite (HA)/reduced graphene oxide (rGO) composites with different mol% of strontium and 1?wt% of GO were fabricated through a green hydrothermal reduction method and this combination has been reported for the first time. All the synthesized composites had strontium incorporated onto the crystal structure of HA as can be substantiated from XRD and FTIR. This paper also discusses a possible role of surface and pore characteristics on the in vitro cytocompatibility and the contribution of graphene oxide in directing the nucleation points resulting in dispersed strontium incorporated hydroxyapatite (SHA) based on P-31 NMR and TEM studies. In addition, a reasonable speculation also has been made to correlate the cytocompatibility with the selective occupancy of strontium ions in the apatite lattice. The in vitro cytocompatibility of SHA/rGO composites (SHAG) has been evaluated using cell proliferation tests with MG-63 cells, under a wider range of concentrations (1000–7.8?µg/ml) and by varying Sr/(Ca+Sr) molar ratio. SHAG with strontium substitution of 10?mol% exhibited the maximum viability among the samples tested. These results suggest that the SHAG composites will be a promising material for biomedical application.     

Functionalized Reduced Graphene Oxide as a Versatile Tool for Cancer Therapy

Cancer is one of the deadliest diseases in human history with extremely poor prognosis. Although many traditional therapeutic modalities—such as surgery, chemotherapy, and radiation therapy—have proved to be successful in inhibiting the growth of tumor cells, their side effects may vastly limited the actual benefits and patient acceptance. In this context, a nanomedicine approach for cancer therapy using functionalized nanomaterial has been gaining ground recently. Considering the ability to carry various anticancer drugs and to act as a photothermal agent, the use of carbon-based nanomaterials for cancer therapy has advanced rapidly. Within those nanomaterials, reduced graphene oxide (rGO), a graphene family 2D carbon nanomaterial, emerged as a good candidate for cancer photothermal therapy due to its excellent photothermal conversion in the near infrared range, large specific surface area for drug loading, as well as functional groups for functionalization with molecules such as photosensitizers, siRNA, ligands, etc. By unique design, multifunctional nanosystems could be designed based on rGO, which are endowed with promising temperature/pH-dependent drug/gene delivery abilities for multimodal cancer therapy. This could be further augmented by additional advantages offered by functionalized rGO, such as high biocompatibility, targeted delivery, and enhanced photothermal effects. Herewith, we first provide an overview of the most effective reducing agents for rGO synthesis via chemical reduction. This was followed by in-depth review of application of functionalized rGO in different cancer treatment modalities such as chemotherapy, photothermal therapy and/or photodynamic therapy, gene therapy, chemotherapy/phototherapy, and photothermal/immunotherapy.     

Overexpression of MicroRNA-30b Improves Adenovirus-Mediated p53 Cancer Gene Therapy for Laryngeal Carcinoma

MicroRNAs play important roles in laryngeal carcinoma and other cancers. However, the expression of microRNAs in paracancerous tissue has been studied less. Here, using laser capture microdissection (LCM), we detected the expression of microRNAs in paracancerous tissues. Among all down-regulated microRNAs in the center area of tumor tissues, only miR-30b expression was significantly reduced in paracancerous tissues compared to surgical margins. Therefore, to further investigate the effect of miR-30b on laryngeal carcinoma, we stably overexpressed miR-30b in laryngeal carcinoma cell line HEp-2 cells. It was found that although there was no significant difference in cell viability between miR-30b overexpressed cells and control HEp-2 cells, p53 expression was obviously enhanced in miR-30b overexpressed cells. Whether miR-30b could improve the anti-tumor effect of adenovirus-p53 (Ad-p53) in laryngeal carcinoma and other cancer cell lines was also evaluated. It was found that in miR-30b overexpressed HEp-2 cells, p53-mediated tumor cell apoptosis was obviously increased both in vitro and in vivo. MDM2-p53 interaction might be involved in miR-30b-mediated anti-tumor effect. Together, results suggested that miR-30b could modulate p53 pathway and enhance p53 gene therapy-induced apoptosis in laryngeal carcinoma, which could provide a novel microRNA target in tumor therapy.     

Novel Insights into the Role of the Mineralocorticoid Receptor in Human Glioblastoma

The majority of glioblastoma (GBM) patients require the administration of dexamethasone (DEXA) to reduce brain inflammation. DEXA activates the glucocorticoid receptor (GR), which can consequently crosstalk with the mineralocorticoid receptor (MR). However, while GR signaling is well studied in GBM, little is known about the MR in brain tumors. We examined the implication of the MR in GBM considering its interplay with DEXA. Together with gene expression studies in patient cohorts, we used human GBM cell lines and patient-derived glioma stem cells (GSCs) to assess the impact of MR activation and inhibition on cell proliferation, response to radiotherapy, and self-renewal capacity. We show that in glioma patients, MR expression inversely correlates with tumor grade. Furthermore, low MR expression correlates with poorer survival in low grade glioma while in GBM the same applies to classical and mesenchymal subtypes, but not proneural tumors. MR activation by aldosterone suppresses the growth of some GBM cell lines and GSC self-renewal. In GBM cells, the MR antagonist spironolactone (SPI) can promote proliferation, radioprotection and cooperate with DEXA. In summary, we propose that MR signaling is anti-proliferative in GBM cells and blocks the self-renewal of GSCs. Contrary to previous evidence obtained in other cancer types, our results suggest that SPI has no compelling anti-neoplastic potential in GBM.     

Enhanced the dispersibility and permeability of silver nanoparticles over rGO grafted by positively-charged polyethyleneimine toward broad-spectrum sterilization

Silver nanoparticles (Ag NPs) are used as antimicrobial agents due to their high-efficiency, broad-spectrum disinfection activity. However, the agglomeration and stability problems caused by excessive release of silver ions (Ag⁺) have severely restricted their developments. Herein, a novel silver/polyethyleneimine/reduced graphene oxide (Ag/PEI/rGO) antibacterial material featuring good dispersibility and permeability was rationally designed, thus benefiting for the capture of bacteria due to the introducing of highly-cationic PEI modifier and controllable release of biocidal agents (Ag⁺). Compared with Ag/rGO, the Ag/PEI/rGO has excellent stability and shows a more efficient sterilization efficacy against Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus) with 100% germicidal efficiency with low orders of dozens of ppm. In addition, the outstanding biocompatibility of this Ag/PEI/rGO antibacterial material endows it with promising potential in sterilization applications, which is expected to solve the infection problem caused by bacterial biofilm formation.     

The Discovery of Potential MDM2 Inhibitors: A Combination of Pharmacophore Modeling,Virtual Screening,Molecular Docking Studies,and in vitro/in vivo Biological Evaluation

Small-molecule inhibitors of MDM2 that block the MDM2-p53 protein-protein interaction have been considered as potential therapeutic agents for the treatment of cancer. Here, we identify five highly potent inhibitors of MDM2 (termed as WY 1–5) that display significant inhibitory effects on MDM2-p53 interaction by using a combined strategy of pharmacophore modeling, virtual screening, and molecular docking studies. Among them, WY-5 is the most active MDM2 inhibitor with an IC₅₀ value of 14.1±2.8 nM. Moreover, WY-5 significantly up-regulate the protein level of p53 in SK-Hep-1 cells harboring wild-type p53. In vitro anticancer study reveals that WY-5 markedly inhibits the survival of SK-Hep-1 cells. In vivo anticancer study suggests that WY-5 significantly inhibits the growth of SK-Hep-1 cells-derived xenograft in nude mice, with no observable toxicity. Our results demonstrate that WY-5 may be a promising candidate for the treatment of cancer harboring wild-type p53.     

The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer

Ovarian cancer is the most lethal gynecological malignancy, with an alarmingly poor prognosis attributed to late detection and chemoresistance. Initially, most tumors respond to chemotherapy but eventually relapse due to the development of drug resistance. Currently, there are no biological markers that can be used to predict patient response to chemotherapy. However, it is clear that mutations in the tumor suppressor gene TP53, which occur in 96% of serous ovarian tumors, alter the core molecular pathways involved in drug response. One subtype of TP53 mutations, widely termed gain-of-function (GOF) mutations, surprisingly converts this protein from a tumor suppressor to an oncogene. We term the resulting change an oncomorphism. In this review, we discuss particular TP53 mutations, including known oncomorphic properties of the resulting mutant p53 proteins. For example, several different oncomorphic mutations have been reported, but each mutation acts in a distinct manner and has a different effect on tumor progression and chemoresistance. An understanding of the pathological pathways altered by each mutation is necessary in order to design appropriate drug interventions for patients suffering from this deadly disease.     

TP53inp1 Gene Is Implicated in Early Radiation Response in Human Fibroblast Cells

Tumor protein 53-induced nuclear protein-1 (TP53inp1) is expressed by activation via p53 and p73. The purpose of our study was to investigate the role of TP53inp1 in response of fibroblasts to ionizing radiation. γ-Ray radiation dose-dependently induces the expression of TP53inp1 in human immortalized fibroblast (F11hT) cells. Stable silencing of TP53inp1 was done via lentiviral transfection of shRNA in F11hT cells. After irradiation the clonogenic survival of TP53inp1 knockdown (F11hT-shTP) cells was compared to cells transfected with non-targeting (NT) shRNA. Radiation-induced senescence was measured by SA-β-Gal staining and autophagy was detected by Acridine Orange dye and microtubule-associated protein-1 light chain 3 (LC3B) immunostaining. The expression of TP53inp1, GDF-15, and CDKN1A and alterations in radiation induced mitochondrial DNA deletions were evaluated by qPCR. TP53inp1 was required for radiation (IR) induced maximal elevation of CDKN1A and GDF-15 expressions. Mitochondrial DNA deletions were increased and autophagy was deregulated following irradiation in the absence of TP53inp1. Finally, we showed that silencing of TP53inp1 enhances the radiation sensitivity of fibroblast cells. These data suggest functional roles for TP53inp1 in radiation-induced autophagy and survival. Taken together, we suppose that silencing of TP53inp1 leads radiation induced autophagy impairment and induces accumulation of damaged mitochondria in primary human fibroblasts.     

Preparation of functional reduced graphene oxide and its influence on the properties of polyimide composites

Homogeneous dispersion and strong filler–matrix interfacial interactions were vital factors for graphene for enhancing the properties of polymer composites. To improve the dispersion of graphene in the polymer matrix and enhance the interfacial interactions, graphene oxide (GO), as an important precursor of graphene, was functionalized with amine‐terminated poly(ethylene glycol) (PEG–NH₂) to prepare GO–poly(ethylene glycol) (PEG). Then, GO–PEG was further reduced to prepare modified reduced graphene oxide (rGO)–PEG with N₂H₄·H₂O. The success of the modification was confirmed by Fourier transform infrared spectroscopy, thermogravimetric analysis, and Raman spectroscopy. Different loadings of rGO–PEG were introduced into polyimide (PI) to produce composites via in situ polymerization and a thermal reduction process. The modification of PEG–NH₂ on the surface of rGO inhibited its reaggregation and improved the filler–matrix interfacial interactions. The properties of the composites were enhanced by the incorporation of rGO–PEG. With the addition of 1.0 wt % rGO–PEG, the tensile strength of PI increased by 81.5%, and the electrical conductivity increased by eight orders of magnitude. This significant improvement was attributed to the homogeneous dispersion of rGO–PEG and its strong filler–matrix interfacial interactions. © 2017 Wiley Periodicals, Inc. J. Appl. Polym. Sci. 2017 , 134, 45119.     

Microfluidic synthesis of ultrasmall Co nanoparticles over reduced graphene oxide and their catalytic properties

We prepared a one-stage microfluidic-based method for continuous synthesis of cobalt (Co) nanoparticles over reduced graphene oxide (rGO) to produce Co/rGO composites. These were generated by the coreduction of Co²⁺ ions and GO with NaBH₄ which was confined within discrete aqueous plugs segmented by octane as continuous phase. Owing to the excellent transfer properties from recirculation in these plugs, ultrasmall Co nanoparticles were distributed homogeneously on the GO sheets without using any surfactants. As compared to batch methods, the average size of Co nanoparticles and the relative standard deviation decreased from 4.0 ± 1.42 nm and 35.9% to 2.0 ± 0.45 nm and 22.6%, respectively. The as-prepared Co/rGO composites exhibited superior activity towards the catalytic reduction of p-nitrophenol to p-aminophenol with NaBH₄ compared with Co nanoparticles and rGO; this enhanced activity could be attributed to the synergistic effect between Co nanoparticles and rGO.     

Somatostatin Receptor Splicing Variant sst5TMD4 Overexpression in Glioblastoma Is Associated with Poor Survival,Increased Aggressiveness Features,and Somatostatin Analogs Resistance

Glioblastoma (GBM) is the most malignant and lethal brain tumor. Current standard treatment consists of surgery followed by radiotherapy/chemotherapy; however, this is only a palliative approach with a mean post-operative survival of scarcely ~12–15 months. Thus, the identification of novel therapeutic targets to treat this devastating pathology is urgently needed. In this context, the truncated splicing variant of the somatostatin receptor subtype 5 (sst5TMD4), which is produced by aberrant alternative splicing, has been demonstrated to be overexpressed and associated with increased aggressiveness features in several tumors. However, the presence, functional role, and associated molecular mechanisms of sst5TMD4 in GBM have not been yet explored. Therefore, we performed a comprehensive analysis to characterize the expression and pathophysiological role of sst5TMD4 in human GBM. sst5TMD4 was significantly overexpressed (at mRNA and protein levels) in human GBM tissue compared to non-tumor (control) brain tissue. Remarkably, sst5TMD4 expression was significantly associated with poor overall survival and recurrent tumors in GBM patients. Moreover, in vitro sst5TMD4 overexpression (by specific plasmid) increased, whereas sst5TMD4 silencing (by specific siRNA) decreased, key malignant features (i.e., proliferation and migration capacity) of GBM cells (U-87 MG/U-118 MG models). Furthermore, sst5TMD4 overexpression in GBM cells altered the activity of multiple key signaling pathways associated with tumor aggressiveness/progression (AKT/JAK-STAT/NF-κB/TGF-β), and its silencing sensitized GBM cells to the antitumor effect of pasireotide (a somatostatin analog). Altogether, these results demonstrate that sst5TMD4 is overexpressed and associated with enhanced malignancy features in human GBMs and reveal its potential utility as a novel diagnostic/prognostic biomarker and putative therapeutic target in GBMs.     

Studies on synergetic effect of rGO-NiCo2S4 nanocomposite as an effective counter electrode material for DSSC

Nanocomposites of reduced graphene oxide (rGO) and NiCo₂S₄ with different amount of graphene oxide (GO) are synthesized through a one- step solvothermal method and their catalytic activity towards I^-/I₃^- redox electrolyte for dye-sensitized solar cell (DSSC) application are reported. The growth mechanism of the pristine hierarchical marigold like microspheres of NiCo₂S₄ that formed without rGO and the nanocomposite of rGO-NiCo₂S₄ are also proposed. Electrochemical studies confirmed the synergetic effect of nickel and cobalt ions with the high electrical conductive rGO networks that enhance the electrocatalytic activity of NiCo₂S₄ nanostructures. The synergistic effect between NiCo₂S₄ and rGO may be attributed to the higher conductivity of rGO and the inverse spinel crystal structure of NiCo₂S₄ that have more octahedral catalytic active sites of Co³⁺. The amount of graphene oxide plays the important role of controlling the DSSC performance and the power conversion efficiency. The efficiency achieved for the rGO-NiCo₂S₄ counter electrode (CE) based DSSC is 8.15%, which is remarkably higher than that of pristine NiCo₂S₄ (7.36%), and Pt (7.23%) under the same experimental conditions.     

Preparation of well‐dispersed reduced graphene oxide and its mechanical reinforcement in polyvinyl alcohol fibre

The current work reports the preparation and characterization of polyvinyl alcohol (PVA) composite fibres reinforced with graphene reduced from graphene oxide (GO) by using oligomeric proanthocyanidin (OPC) as a reductant. After reduction, most of the oxygen‐containing groups were removed from the GO and reduced graphene oxide (rGO) was prepared. As a result of combined OPC as a dispersant, rGO could be well dispersed in a dimethyl sulfoxide/H₂O mixed solvent and in PVA matrix, and the PVA/rGO dispersion was wet spun followed by hot drawing to prepare continuous PVA/rGO composite fibres. The PVA/rGO composite fibres exhibited a significant enhancement of mechanical properties at low rGO loadings; in particular the tensile strength and Young's modulus of the 2.0 wt% rGO and PVA composite fibre increased to 244% and 294% respectively relative to neat PVA fibre. Moreover, the storage modulus (?10 °C) and T_g increased to 300% and 7.2 °C, respectively. © 2016 Society of Chemical Industry     

Enhanced optical properties of ZnS–rGO nanocomposites for ultraviolet detection applications

In this research, fabrication and characterization of ultraviolet (UV) detectors based on zinc sulfide–reduced graphene oxide (rGO) nanocomposite with the focus on the wurtzite structure of zinc sulfide was carried out. The nanoparticles of ZnS were synthesized using chemical deposition method and annealed at 500?°C under flow of argon. X-ray diffraction pattern showed that ZnS with the wurtzite phase was formed at 500?°C. Here, rGO as a unique material with similar properties to graphene such as high electron transport was used in order to improve the optical properties of ZnS. For this purpose, rGO was added to ZnS with three different weight percentages of 5, 10 and 15. Scanning electron microscopy showed that ZnS nanoparticles were well placed in rGO sheets. The UV–visible spectra of the synthesized composites showed that with increasing rGO in composite, light absorption is increased. Photoluminescence (PL) spectra also showed that with increasing the percentage of rGO the generation of electron-hole in composite was increased and PL peak was enhanced. The effect of elevated generation of electron-hole pairs was apparent in optoelectrical properties of fabricated UV detectors based on the sample with higher concentration of rGO in composite. For this sample, the response time was decreased to 310 ms, and the sensitivity to UV irradiation was increased by 7.7 times.     

Bifunctional ternary manganese oxide/vanadium oxide/reduced graphene oxide as electrochromic asymmetric supercapacitor

A bifunctional ternary manganese oxide/vanadium oxide/reduced graphene oxide (MnO₂/V₂O₅/rGO) was developed for asymmetric electrochromic supercapacitor (EC-SC) application. The elemental mapping revealed uniformly distributed MnO₂, V₂O₅ and rGO, depicting homogenous synthesis of the hybrid composite. The phase composition, vibration modes and valance state of the ternary composite were analyzed via X-ray diffraction (XRD), Raman spectroscopy and X-ray photoelectron spectroscopy (XPS) analysis, respectively. Interestingly, the as-prepared MnO₂/V₂O₅/rGO composite disclosed tremendous C_sp of 1403.5 F/g, which was higher compared to MnO₂/V₂O₅ (801.1 F/g), V₂O₅ (613.1 F/g), MnO₂ (126.7 F/g) and rGO (60.7 F/g). MnO₂/V₂O₅/rGO that appeared in dark green switched its visual color to orange at the charged state, confirming the electrochromic property. The bifunctional manganese oxide/vanadium oxide/reduced graphene oxide//copper-based metal-organic framework/reduced graphene oxide (MnO₂/V₂O₅/rGO//MrGO) asymmetrical EC-SC device revealed outstanding cycling stability (90.3% charge retention over 5000 cycles), tremendous specific capacitance (652.7 F/g) and maximum specific energy (60.4 Wh/kg). MnO₂/V₂O₅/rGO//MrGO asymmetrical EC-SC device demonstrated reversible color changes from dark green to orange at the discharged and charged states, respectively. The significantly great electrochromic and supercapacitive performance revealed that MnO₂/V₂O₅/rGO//MrGO is an outstanding electroactive candidate for the next generation of electrochromic supercapacitors.